Technical Analysis for ACLX - Arcellx, Inc.

Grade Last Price % Change Price Change
B 100.48 -5.68% -6.05
ACLX closed down 5.68 percent on Tuesday, November 12, 2024, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Outside Day Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -5.68%
Pocket Pivot Bullish Swing Setup -5.68%

   Recent Intraday Alerts

Alert Time
Down 5% about 6 hours ago
Down 1 ATR about 6 hours ago
Down 3% about 9 hours ago
Outside Day about 9 hours ago
Fell Below Previous Day's Low about 9 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arcellx, Inc. Description

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Its lead ddCAR product candidate is CART-ddBCMA, which is in Phase 1 clinical development for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The company is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Organ Systems Acute Myeloid Leukemia Immunotherapies Multiple Myeloma Protein Kinase Inhibitor Myelodysplastic Syndrome Antibody Drug Conjugate

Is ACLX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 107.3699
52 Week Low 46.43
Average Volume 570,976
200-Day Moving Average 66.09
50-Day Moving Average 84.45
20-Day Moving Average 91.51
10-Day Moving Average 93.30
Average True Range 5.22
RSI (14) 64.54
ADX 23.08
+DI 35.06
-DI 23.36
Chandelier Exit (Long, 3 ATRs) 91.71
Chandelier Exit (Short, 3 ATRs) 92.66
Upper Bollinger Bands 104.50
Lower Bollinger Band 78.51
Percent B (%b) 0.85
BandWidth 28.41
MACD Line 4.62
MACD Signal Line 3.19
MACD Histogram 1.4255
Fundamentals Value
Market Cap 5.22 Billion
Num Shares 51.9 Million
EPS -2.65
Price-to-Earnings (P/E) Ratio -37.92
Price-to-Sales 71.43
Price-to-Book 12.01
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 111.62
Resistance 3 (R3) 112.68 110.02 109.76
Resistance 2 (R2) 110.02 107.19 109.49 109.14
Resistance 1 (R1) 105.25 105.43 103.92 104.19 108.52
Pivot Point 102.60 102.60 101.93 102.07 102.60
Support 1 (S1) 97.83 99.76 96.50 96.77 92.44
Support 2 (S2) 95.17 98.01 94.64 91.82
Support 3 (S3) 90.40 95.17 91.20
Support 4 (S4) 89.34